Natco Pharma gets approval for Everolimus tablets for Oral Suspension for subependymal giant cell astrocytoma

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-01-30 06:00 GMT | Update On 2025-01-30 07:04 GMT

Hyderabad: NATCO Pharma Limited, an Indian pharmaceutical company, has announced the approval of its Abbreviated New Drug Administration (ANDA) for Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

NATCO’s marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc plans to launch the product immediately in the US market.

Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex (“TSC”) for the treatment of subependymal giant cell astrocytoma (“SEGA”) that requires therapeutic intervention but cannot be curatively resected.

Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, had estimated sales of USD 112 million in the U.S. for 12 months ending Sep’24 as per industry sales data.

Read also: Natco Pharma names Imtiyaz Basade as Senior Vice President - RAD, Pharma Division, Kothur Unit

Medical Dialogues team had earlier reported that Natco Pharma had announced the submission of an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with the U.S. Food and Drug Administration (USFDA) for the generic version of EVRYSDI (Risdiplam) 0.75 mg/mL For Oral Solution.

NATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Natco Pharma gets approval for Everolimus tablets for Oral Suspension for subependymal giant cell astrocytoma

Similar News

Ravenbhel's Bilastine, Montelukast FDC Under Review, CDSCO Panel Seeks Pediatric Expert Opinion

From Breakthrough to Backlash: Novo Nordisk's Ozempic Faces USD 2 Billion Lawsuit

Aurobindo Pharma Clarifies Zentiva Acquisition Reports 'Premature', No Binding Pact Finalised

CDSCO Digitisation Cuts Post-Approval Change Timelines in CGTs from 218 to 98 Days: DCGI

PLI scheme brings down cost of rare disease treatment from crores to lakhs

Aurobindo Pharma in lead to acquire Zentiva for US 5.5 billion: ET Report

Parexel appoints Jim Anthony to expanded role as CCO, President, Parexel Biotech

Gas leak at Maha Pharma co kills 4, injures 2